Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer
Guvern
International Association for the Study of Lung Cancer Sep 10 2025 A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). The results were presented at the International Association for the Study of Lung Cancer at the 2025 World Conference on
din zilele anterioare